• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Investors May Respond To Amylyx Pharmaceuticals Stock After Wider Q3 Loss

    Simply Wall St·11/14/2026 15:18:39
    Listen to the news
    • Amylyx Pharmaceuticals reported third quarter 2026 results with a net loss of US$45.49 million and basic and diluted loss per share of US$0.38, while the nine month net loss reached US$130.2 million with basic and diluted loss per share of US$1.15.
    • The widening quarterly loss alongside slightly lower year to date loss per share highlights continued investment in the pipeline and cost structure as Amylyx Pharmaceuticals advances its development programs without current product revenue.
    • We will look at how Amylyx Pharmaceuticals' larger quarterly net loss shapes the investment narrative built around its pre revenue pipeline.

    Scan beyond Amylyx Pharmaceuticals' widening losses and compare other pre revenue healthcare developers through a curated list of 36 healthcare AI stocks that are also betting heavily on future pipelines.

    Amylyx Pharmaceuticals Investment Narrative Recap

    To own Amylyx Pharmaceuticals, you need to believe its pre revenue pipeline in post bariatric hypoglycemia and rare neurodegeneration can eventually justify the current cash burn and quarterly losses. The analyst consensus Narrative on Simply Wall St frames avexitide and the LUCIDITY Phase III trial as central to that thesis. The recent Q3 loss simply reinforces how dependent the story is on getting that first approval right.

    The short term swing factor still looks like upcoming LUCIDITY data and any progress toward an NDA filing. The biggest operational risk is straightforward. LUCIDITY underperformance or rising development costs could extend the loss making period and increase the odds of future capital raises that would dilute existing holders.

    The Q3 2026 earnings release on November 5 is the clearest recent marker for this story. Management reported a net loss of US$45.49 million for the quarter and US$130.2 million for the first nine months of 2026, with basic and diluted loss per share of US$0.38 and US$1.15 respectively. Those figures underline that Amylyx Pharmaceuticals remains firmly in investment mode without commercial inflows.

    For a catalyst driven idea like this, that update matters mainly as a timing and runway check around LUCIDITY and avexitide. Higher operating spend tied to GLP 1 antagonist programs and neurodegeneration assets keeps execution risk front and centre. If trial milestones or regulatory steps slip, ongoing losses at this scale could bring funding and dilution back into focus more quickly than some investors might prefer.

    Amylyx Pharmaceuticals' narrative projects US$343.4 million revenue and US$86.8 million earnings by 2029. This implies earnings would need to increase by about US$239 million from earnings today of a US$152.1 million loss.

    Uncover why Amylyx Pharmaceuticals' fair value indicates a 40% potential upside to its current price before the market closes that gap.

    NasdaqGS:AMLX 1-Year Stock Price Chart
    NasdaqGS:AMLX 1-Year Stock Price Chart

    Exploring Other Perspectives

    Some of the most optimistic analysts anchor their story to avexitide’s commercial rollout rather than today’s Amylyx Pharmaceuticals loss. Before this Q3 report, that group was mapping out US$567.5 million of revenue and US$82.1 million of earnings by 2029. You can treat this as one end of a wide spectrum of views that may shift as new information lands.

    Explore another Amylyx Pharmaceuticals fair value estimate, including one that suggests there could be as much as 545% upside from the current price!

    Decide For Yourself

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    Looking For More Investment Ideas Beyond Amylyx Pharmaceuticals?

    If Amylyx Pharmaceuticals has you thinking about risk, reward, and timing, it can help to compare it with other opportunities that fit clear criteria. A good screener lets you filter for the traits you care about so every idea you research already matches your basic checklist.